Literature DB >> 1818205

Yeast glucan of Pneumocystis carinii cyst wall: an excellent target for chemotherapy.

Y Matsumoto1, M Yamada, T Amagai.   

Abstract

Pneumocystis pneumonia is the most serious opportunistic infection in immunocompromised patients, particularly those with AIDS. Approved therapy is limited to pentamidine and inhibitors of folic acid synthesis, but these drugs show a high rate of adverse reactions in AIDS patients emphasizing the urgent need for additional effective therapies. Progress has, however, been hindered by lack of knowledge about this parasite's cellular characteristics. Previously we reported that beta (1,3)glucan is a major component of the Pneumocystis carinii cyst wall. This study shows that administration of aculeacin A, an inhibitor of beta (1,3)glucan biosynthesis, affects cyst wall formation, inhibits cyst maturation, and prevents severe pneumonia in steroid-treated rats. Thus this study not only demonstrates that beta (1,3)glucan is indispensable for growth of the parasite in rats, but suggests a new therapeutic strategy for human pneumocystosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1818205

Source DB:  PubMed          Journal:  J Protozool        ISSN: 0022-3921


  6 in total

1.  Characterization of N-Acetylglucosamine Biosynthesis in Pneumocystis species. A New Potential Target for Therapy.

Authors:  Theodore J Kottom; Deanne M Hebrink; Paige E Jenson; Jorge H Ramirez-Prado; Andrew H Limper
Journal:  Am J Respir Cell Mol Biol       Date:  2017-02       Impact factor: 6.914

Review 2.  Pneumocystis carinii: what is it, exactly?

Authors:  J R Stringer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

3.  Characterization of a distinct host response profile to Pneumocystis murina asci during clearance of pneumocystis pneumonia.

Authors:  Michael J Linke; Alan Ashbaugh; Margaret S Collins; Keeley Lynch; Melanie T Cushion
Journal:  Infect Immun       Date:  2013-01-14       Impact factor: 3.441

Review 4.  A Molecular Window into the Biology and Epidemiology of Pneumocystis spp.

Authors:  Liang Ma; Ousmane H Cissé; Joseph A Kovacs
Journal:  Clin Microbiol Rev       Date:  2018-06-13       Impact factor: 26.132

Review 5.  Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.

Authors:  P D Walzer; J Foy; P Steele; M White
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

6.  Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice.

Authors:  Maria Luísa Lobo; Francisco Esteves; Bruno de Sousa; Fernando Cardoso; Melanie T Cushion; Francisco Antunes; Olga Matos
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.